Your browser is no longer supported. Please, upgrade your browser.
ADiTx Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.73 Insider Own25.02% Shs Outstand14.00M Perf Week-8.13%
Market Cap46.75M Forward P/E1.11 EPS next Y2.90 Insider Trans0.00% Shs Float9.62M Perf Month2.22%
Income-5.50M PEG- EPS next Q-0.07 Inst Own5.30% Short Float7.97% Perf Quarter65.13%
Sales- P/S- EPS this Y-2.40% Inst Trans-14.92% Short Ratio0.19 Perf Half Y-16.15%
Book/sh1.85 P/B1.74 EPS next Y222.22% ROA-133.80% Target Price- Perf Year-
Cash/sh0.94 P/C3.41 EPS next 5Y- ROE-596.90% 52W Range1.62 - 9.58 Perf YTD54.81%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-66.39% Beta-
Dividend %- Quick Ratio18.90 Sales past 5Y- Gross Margin- 52W Low98.77% ATR0.57
Employees2 Current Ratio18.90 Sales Q/Q- Oper. Margin- RSI (14)46.70 Volatility9.14% 12.84%
OptionableYes Debt/Eq0.00 EPS Q/Q26.20% Profit Margin- Rel Volume0.08 Prev Close3.22
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume4.05M Price3.22
Recom- SMA20-13.17% SMA507.45% SMA20011.91% Volume0 Change0.00%
Jan-29-21 09:24AM  
Jan-26-21 08:54AM  
Jan-21-21 08:00AM  
Dec-14-20 08:00AM  
Dec-08-20 08:00AM  
Nov-30-20 08:30AM  
Nov-22-20 11:27PM  
Nov-20-20 08:00AM  
Nov-19-20 08:30AM  
Nov-13-20 08:00AM  
Oct-02-20 04:05PM  
Oct-01-20 08:00AM  
Sep-10-20 04:30PM  
Sep-03-20 09:00AM  
Sep-02-20 08:30AM  
Aug-31-20 05:00PM  
Aug-27-20 08:30AM  
Aug-25-20 08:00AM  
Aug-24-20 08:30AM  
Aug-14-20 08:00AM  
Aug-06-20 08:00AM  
Aug-03-20 08:00AM  
Jul-24-20 08:00AM  
Jul-22-20 08:00AM  
Jul-21-20 08:00AM  
Jul-16-20 11:00AM  
Jul-10-20 08:00AM  
Jul-06-20 04:46PM  
Jul-02-20 04:10PM  
Jun-30-20 09:49AM  
ADiTx Therapeutics, Inc., a life sciences company, develops technologies focuses on improving the health of the immune system through immune monitoring and reprogramming. It is developing AditxtScore that allow individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach, which mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. It has a license agreement with Loma Linda University and Leland Stanford Junior University. ADiTx Therapeutics, Inc. was founded in 2017 and is headquartered in Mountain View, California.